Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 1.00 |
| ▸ | DDB1 | Q16531 | 10/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TNKS | O95271 | 3/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31040970 | 1.00 | CRBN (1.00) | CRBNDDB1ALOX5MAPTTNKS | |
| SCHEMBL30267234 | 0.84 | CRBN (0.71) | CRBNDDB1ALOX5MAPTTNKS | |
| SCHEMBL31607788 | 0.84 | CRBN (0.72) | CRBNDDB1ALOX5MAPTTNKS | |
| SCHEMBL2536247 | 0.84 | DDB1 (0.72) | CRBNDDB1ALOX5MAPTSMN1; SMN2 | |
| SCHEMBL31040943 | 0.81 | CRBN (0.69) | CRBNDDB1ALOX5MAPTTNKS | |
| SCHEMBL24204354 | 0.80 | CRBN (0.67) | CRBNDDB1MEN1ALDH1A1KMT2A | |
| SCHEMBL25122532 | 0.80 | CRBN (0.67) | CRBNDDB1ALOX5MAPTMEN1 | |
| SCHEMBL31607808 | 0.80 | CRBN (0.67) | CRBNDDB1MEN1ALDH1A1KMT2A | |
| SCHEMBL31607797 | 0.79 | CRBN (0.66) | CRBNDDB1ALOX5TNKSTNKS2 | |
| SCHEMBL31393524 | 0.79 | CRBN (0.66) | CRBNDDB1TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393922-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| CN-116940571-A | Benzisoxazole derivative and use thereof | 诺华股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| EP-4194457-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | CRBN 221/4885DDB1 1973/4885ALOX5 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.